ABCL FY2025 SEC EDGAR DEF 14A #67 of 168 in industry

AbCellera Biologics Inc. CEO pay ratio

The CEO earned $6.4M in FY2025 against median worker pay of $122,119 · Chemicals & Pharmaceuticals.

Chemicals & Pharmaceuticals peers All rankings
State
A1
Filing date
2026-04-29
Industry
Chemicals & Pharmaceuticals
Industry rank
#67/168

Data updated August 2026

Subscribe to AbCellera Biologics Inc. CEO pay filing updates (RSS)

CEO-to-worker pay ratio
52:1
Moderate (Scale: 0–1000:1)
CEO pay
$6.4M
Median worker
$122,119

Answer first

AbCellera Biologics Inc.'s FY2025 CEO total of $6.4M ranks #819 of 1,423 complete filings; its 52:1 pay ratio ranks #958. Dollar rank is not ratio rank.

According to the same FY2025 complete-filing cohort used on the rankings boards (CEO total, median worker, and ratio all present). Median worker pay is $122,119. Industry placement uses the FY2025 SIC-28 peer cohort (# 67 of 168, 61st percentile - above the industry median pay ratio). Figures come from Section 953(b) Dodd-Frank DEF 14A disclosures - not estimates. View all Chemicals & Pharmaceuticals companies.

Dollar rank
#819
$6.4M of 1,423 FY2025
Ratio rank
#958
52:1 of 1,423
Industry pct
61st
above the industry median pay ratio

How AbCellera Biologics Inc. ranks nationally

AbCellera Biologics Inc. CEO pay vs. every FY2025 complete filing

Total CEO compensation, the full national distribution, this company marked

$6,350,188 42nd percentile higher than 42% of 1,423 companies

$0–$2,500,000: 304 companies (21%). Below this entry. $2,500,000–$5,000,000: 182 companies (13%). Below this entry. $5,000,000–$7,500,000: 208 companies (15%). This entry sits in this band. $7,500,000–$10,000,000: 192 companies (13%). Above this entry. $10,000,000–$12,500,000: 139 companies (10%). Above this entry. $12,500,000–$15,000,000: 91 companies (6%). Above this entry. $15,000,000–$17,500,000: 88 companies (6%). Above this entry. $17,500,000–$20,000,000: 54 companies (4%). Above this entry. $20,000,000–$22,500,000: 24 companies (2%). Above this entry. $22,500,000–$25,000,000: 34 companies (2%). Above this entry. $25,000,000–$27,500,000: 24 companies (2%). Above this entry. $27,500,000–$30,000,000: 16 companies (1%). Above this entry. $30,000,000–$32,500,000: 10 companies (1%). Above this entry. $32,500,000–$35,000,000: 7 companies (0%). Above this entry. $35,000,000–$37,500,000: 9 companies (1%). Above this entry. $37,500,000–$40,000,000: 6 companies (0%). Above this entry. $40,000,000–$42,500,000: 1 companies (0%). Above this entry. $42,500,000–$45,000,000: 1 companies (0%). Above this entry. $45,000,000–$47,500,000: 6 companies (0%). Above this entry. $47,500,000–$50,000,000: 27 companies (2%). Above this entry. This company $0 $50M+ every complete-filing company, bucketed by value

Each bar is a $2500K-wide band; taller bars hold more companies. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.

Source SEC DEF 14A Section 953(b) disclosures, PlainCEOPay extract · FY2025

AbCellera Biologics Inc. vs. Chemicals & Pharmaceuticals peers

CEO total pay ($6.4M) against pay ratio (52:1) for AbCellera Biologics Inc. (marked) and its 4 closest same-industry peers, against the Chemicals & Pharmaceuticals industry median on both axes.

Pay + gap both highContained pay, wide gapHigh pay, contained gapBelow peer norms on both4568585.58942721.81331685817690994.322065130.541.4:144.7:148:151.3:154.6:1CEO total payPay ratio (CEO : median worker)AbCellera Biologics Inc., CEO total pay: 6350188 · Pay ratio (CEO : median worker): 52:1AbCellera Biologics Inc.AdvanSix Inc., CEO total pay: 5647438 · Pay ratio (CEO : median worker): 51:1AdvanSix Inc.Prestige Consumer Healthcare Inc., CEO total pay: 6004547 · Pay ratio (CEO : median worker): 54:1Prestige Consumer Healthcare Inc.Viking Therapeutics, Inc., CEO total pay: 21269833 · Pay ratio (CEO : median worker): 49:1Viking Therapeutics, Inc.Lsb Industries, Inc., CEO total pay: 5363883 · Pay ratio (CEO : median worker): 49:1Lsb Industries, Inc.
AbCellera Biologics Inc. vs. Chemicals & Pharmaceuticals peers, plotted against the industry's $7.9M median CEO total and 42:1 median pay ratio.

Ratio bands among Chemicals & Pharmaceuticals peers

Exclusive CEO-to-median-worker bands across 153 complete latest-FY filings in SIC 28. Segments sum to the peer set, not this company's compensation pillar.

CEO Compensation Breakdown, FY2025

A component-level pay breakdown is not reported in AbCellera Biologics Inc.'s structured SEC pay-ratio disclosure. See our methodology →

Filing-year trail · AbCellera Biologics Inc.

Complete DEF 14A pay-ratio filings for this CIK across FY2022–2025. Year-over-year deltas compare adjacent filing years only; incomplete dollar rows are omitted (same completeness gate as the hero figures).

Latest ratio
52:1
FY2025
vs prior FY
-11:1
from FY2024 63:1
CEO $ YoY
-23%
$6.4M latest
Filings shown
4
FY2022–2025
AbCellera Biologics Inc. CEO total compensation, median worker pay, and pay ratio by fiscal year from SEC EDGAR DEF 14A.
FY CEO pay Δ pay Median worker Pay ratio Δ ratio
2022 $8.7M - $164,570 53:1 -
2023 $756K -91% $125,928 6:1 -47:1
2024 $8.3M +997% $131,608 63:1 +57:1
2025 $6.4M -23% $122,119 52:1 -11:1

Source: SEC EDGAR DEF 14A pay-ratio disclosures for CIK 1703057, FY2022–2025. Adjacent-year deltas only.

Industry Comparison - Chemicals & Pharmaceuticals

This Company's Ratio
52:1
Industry Median Ratio
42:1
Industry Median CEO Pay
$7.9M
This CEO's Pay
$6.4M
Companies in Industry
168
vs. Industry Median
Above
#67 of 168 by pay ratio in this industry View all companies in Chemicals & Pharmaceuticals →

AbCellera Biologics Inc.: MODEST · HEAVY pay ratio

AbCellera Biologics Inc.'s 52:1 ratio ranks #958 of 1,423 FY2025 complete filings (lower third by ratio). the CEO earned 52× the median employee ($122,119) in FY2025.

Median employee $122,119 (ELITE-MED); MODEST · HEAVY stamps put about 52 median-wage years per CEO year.

CEO Total Pay

$6.4M

FY2025 Summary Compensation, below median

Pay Ratio

52:1

Near industry median

AbCellera Biologics Inc. in the lower-ratio third

AbCellera Biologics Inc.'s 52:1 ratio ranks #958 of 1,423 FY2025 complete filings (lower third by ratio). The structured pay-ratio disclosure reports the total without line-item components. Chemicals & Pharmaceuticals (SIC 28) median ratio is 42:1 across 168 FY2025 filers; AbCellera Biologics Inc.'s $6.4M CEO total is at or below the $7.9M industry median CEO pay.

Dollar rank #819 and ratio rank #958 split - treat 52:1 as a disclosure, not a fairness score. Open Chemicals & Pharmaceuticals peers.

Key Data, FY2025

Total Compensation
$6.4M
Median Employee Pay
$122,119
Pay Ratio
52:1
Filing Date
2026-04-29

Company Info

Ticker
ABCL
CIK
1703057
Industry
Chemicals & Pharmaceuticals
SIC Code
2834
State
A1
View SEC filings →
SEC EDGAR DEF 14A for CIK 1703057, FY2025. Informational only, not investment advice. Verify on EDGAR.

Read our methodology - how this data is sourced, computed, and verified. AbCellera Biologics Inc.'s 52:1 ratio ranks #958 of 1,423 FY2025 complete filings (lower third by ratio).

Read with AbCellera Biologics Inc.

ABS(ceo_total_comp) peers first, then a SIC pole and a stamp-branched guide - not a fixed Related strip. This page stamps MODEST · HEAVY · ELITE-MED.

Associated Banc-corp · HEAVY

ABS(ceo_total_comp) peer at $6.4M (Δ $4K heavier vs AbCellera Biologics Inc.); MID · PAR-MED vs this page's MODEST · HEAVY · ELITE-MED.
Uranium Energy Corp · HEAVY

ABS(ceo_total_comp) peer at $6.4M (Δ $6K heavier vs AbCellera Biologics Inc.); MID · PAR-MED vs this page's MODEST · HEAVY · ELITE-MED.
Compass Minerals International Inc · HEAVY

ABS(ceo_total_comp) peer at $6.3M (Δ $16K lighter vs AbCellera Biologics Inc.); MODEST · HIGH-MED vs this page's MODEST · HEAVY · ELITE-MED.
10x Genomics, Inc. · HEAVY

ABS(ceo_total_comp) peer at $6.3M (Δ $21K lighter vs AbCellera Biologics Inc.); MODEST · ELITE-MED vs this page's MODEST · HEAVY · ELITE-MED.
Novavax Inc (SIC 28 pole)

Novavax Inc stamps MODEST · UNFILED nearest in-SIC by ABS(pay_ratio) to AbCellera Biologics Inc.'s MODEST filing.
National dual ranks · #819/#958

AbCellera Biologics Inc.'s FY2025 package sits #819 by CEO dollars and #958 by ratio under HEAVY · MODEST.
Ratio primer · MODEST

AbCellera Biologics Inc.'s MODEST stamp sits in the lower Item 402(u) band - start with how the ratio is disclosed before comparing peers.
Data sourced from SEC EDGAR DEF 14A for AbCellera Biologics Inc. (CIK 1703057), FY2025. See our methodology. Aggregated by PlainCEOPay as of August 2026.

Data currency: Executive compensation from SEC EDGAR DEF 14A proxy statements through fiscal year 2025, compiled and last refreshed August 2026. See our methodology for source dates and refresh cadence. Spot a figure that looks wrong? Report a correction.